- Home
- ACET vs JAGU Comparison
ACET vs JAGU Comparison
Compare ACET & JAGU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ACET | JAGU |
|---|---|---|
| Founded | 1947 | 2022 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.3M | 63.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ACET | JAGU |
|---|---|---|
| Price | $6.98 | $3.19 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $65.33 | N/A |
| AVG Volume (30 Days) | 201.4K | ★ 860.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.41 | $3.05 |
| 52 Week High | $17.44 | $5.50 |
Technical Indicators
Market Signals| Indicator | ACET | JAGU |
|---|---|---|
| Relative Strength Index (RSI) | 51.12 | N/A |
| Support Level | $6.42 | N/A |
| Resistance Level | $7.30 | N/A |
| Average True Range (ATR) | 0.62 | 0.00 |
| MACD | -0.30 | 0.00 |
| Stochastic Oscillator | 28.38 | 0.00 |
Price Performance
Historical ComparisonAbout ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.